Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Notal Vision’s ForeseeHome AMD Monitoring Program is FDA-cleared and Medicare-reimbursed for home-based monitoring of intermediate dry AMD patients at risk of progression to wet AMD. The program demonstrated in the AREDS2 HOME Study that 94% of patients using ForeseeHome who progressed to wet AMD maintained 20/40 or better vision, compared to only 62% with standard care. The company’s pipeline includes a home-based Optical Coherence Tomography (OCT) device for exudative retinal disease management, which has entered clinical evaluation and is anticipated to reach the market within two years[2][5].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Notal Vision.